Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

(2020) Jean van Wyk et al.   CLINICAL INFECTIOUS DISEASES

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation

(2020) OT Stirrup et al.   HIV MEDICINE

Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients

(2020) Nadia Galizzi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients

(2020) Aude Jary et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

(2020) Rosa De Miguel et al.   EBioMedicine

High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia

(2020) Michael R. Jordan et al.   MEDICINE

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

(2019) Alberto Borghetti et al.   BMC INFECTIOUS DISEASES

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

(2019) Michael Aboud et al.   LANCET INFECTIOUS DISEASES

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

(2019) Gianmaria Baldin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda

(2018) Emmanuel Ndashimye et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations

(2018) Erik Sörstedt et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

(2018) Jose L Blanco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis

(2018) Ravindra K Gupta et al.   LANCET INFECTIOUS DISEASES

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

(2018) Roberta Gagliardini et al.   Open Forum Infectious Diseases

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

(2018) Véronique Joly et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load

(2017) Massimiliano Lanzafame et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

(2017) L. Assoumou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

(2017) Nicolas A. Margot et al.   JOURNAL OF INFECTIOUS DISEASES

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

(2017) John Gregson et al.   LANCET INFECTIOUS DISEASES

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration

(2017) Thibault Mesplède et al.   mBio

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

(2016) Maureen Oliveira et al.   AIDS

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients

(2016) Lisa K Naeger et al.   ANTIVIRAL THERAPY

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

(2016) Jhon Rojas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

(2016) C. Katlama et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1.

(2016) A. Borghetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

(2016) John Gregson et al.   LANCET INFECTIOUS DISEASES

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

(2016) Hanh T. Pham et al.   Retrovirology

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

(2015) Soo-Yon Rhee et al.   PLoS One

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

(2014) Maureen Oliveira et al.   AIDS

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

(2012) Henry Sunpath et al.   AIDS

Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies

(2012) R. L. Hamers et al.   CLINICAL INFECTIOUS DISEASES

Transmission dynamics of the M184V drug resistance mutation in primary HIV infection

(2011) M. A. Wainberg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study

(2011) Raph L Hamers et al.   LANCET INFECTIOUS DISEASES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First‐Line Antiretroviral Therapy in South Africa

(2009) Christopher J. Hoffmann et al.   CLINICAL INFECTIOUS DISEASES

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

(2009) Ravindra K Gupta et al.   LANCET INFECTIOUS DISEASES

In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine

(2008) R. Paredes et al.   JOURNAL OF VIROLOGY